Trial reportJournal of clinical psychopharmacology2014
A randomized, double-blind, placebo-controlled pilot study of naltrexone to counteract antipsychotic-associated weight gain: proof of concept.
Trial report in Journal of clinical psychopharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00793780 (Pilot Trial of Naltrexone for Obesity in Women With Schizophrenia), which is not on this map. Cited by 16 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pilot Trial of Naltrexone for Obesity in Women With Schizophrenia
Who cites it
16 citing papers in PubMed, 7 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- Centrally-acting opioid receptor antagonists as a treatment for antipsychotic-induced weight gain: A systematic review and meta-analysis of clinical trial data.Journal of psychopharmacology (Oxford, England) · 2025Pooled it
- Pharmacological interventions for prevention of weight gain in people with schizophrenia.The Cochrane database of systematic reviews · 2022Pooled it
- Disordered Eating among People with Schizophrenia Spectrum Disorders: A Systematic Review.Nutrients · 2021Pooled it
- A meta-analysis comparing short-term weight and cardiometabolic changes between olanzapine/samidorphan and olanzapine.Scientific reports · 2021Pooled it
- Pharmacological Interventions to Treat Antipsychotic-Induced Dyslipidemia in Schizophrenia Patients: A Systematic Review and Meta Analysis.Frontiers in psychiatry · 2021Pooled it
- Opioid antagonists are associated with a reduction in the symptoms of schizophrenia: a meta-analysis of controlled trials.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2020Pooled it
- The Effectiveness of Pharmacological and Non-Pharmacological Interventions for Improving Glycaemic Control in Adults with Severe Mental Illness: A Systematic Review and Meta-Analysis.PloS one · 2017 · on this mapPooled it
- Errors in Liu et al. 'Safety and effects of anti-obesity medications on weight loss, cardiometabolic, and psychological outcomes in people living with overweight or obesity: a systematic review and meta-analysis'.EClinicalMedicine · 2026Article
- A Systematic Review on the Potential of Aspirin to Reduce Cardiovascular Risk in Schizophrenia.Brain sciences · 2023Review
- Opioid antagonists to prevent olanzapine-induced weight gain: A systematic review.The mental health clinician · 2022Review
- Safety and efficacy of naltrexone for weight loss in adult patients - a systematic review.Archives of medical science : AMS · 2021Review
- Management of common adverse effects of antipsychotic medications.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2018Article
- Antipsychotic Drugs: From Receptor-binding Profiles to Metabolic Side Effects.Current neuropharmacology · 2018Review
- Topiramate and Metformin Are Effective Add-On Treatments in Controlling Antipsychotic-Induced Weight Gain: A Systematic Review and Network Meta-Analysis.Frontiers in pharmacology · 2018Review
- Substance Use Disorders and Schizophrenia.Focus (American Psychiatric Publishing) · 2016Article
- Naltrexone HCI/bupropion HCI for chronic weight management in obese adults: patient selection and perspectives.Patient preference and adherence · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
Patients with schizophrenia experience higher rates of obesity as well as related morbidity and mortality than the general population does. Women with schizophrenia are at particular risk for antipsychotic-associated weight gain, obesity, and related medical disorders such as diabetes and cardiovascular disease. Given preclinical studies revealing the role of the endogenous opioid systems in human appetite and the potential of antipsychotic medications to interfere with this system, we hypothesized that opioid antagonists may be beneficial in arresting antipsychotic-associated weight gain and promoting further weight loss in women with schizophrenia. In the present study, 24 overweight women with a diagnosis of schizophrenia or schizoaffective disorder were randomized to placebo or naltrexone (NTX) 25 mg/d for 8 weeks. The primary outcome measure was a change in body weight from baseline. The patients in the NTX group had significant weight loss (-3.40 kg) compared with weight gain (+1.37 kg) in the patients in the placebo group. Mainly, nondiabetic subjects lost weight in the NTX arm. These data support the need to further investigate the role of D2 blockade in reducing food reward-based overeating. A larger study addressing the weaknesses of this pilot study is currently underway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.